Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL29635996 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL3064 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL580446 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29379290 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL36882 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1260827 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL9221238 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL617185 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1262758 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 916 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4088717-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2022-11-16 | — | — | EP | claimed |
| EP-3104848-B1 | INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT | CRYSTEC LTD (GB) | 2020-05-06 | — | — | EP | claimed |
| CN-106163505-B | Improvements relating to inhalable particles | 科瑞思特有限公司 | 2020-04-24 | — | — | CN | claimed |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2019-10-17 | — | — | US | claimed |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | CHASE PHARMACEUTICALS CORP (US) | 2019-03-28 | — | — | US | claimed |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-12-20 | — | — | US | claimed |
| EP-3324966-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | Chase Pharmaceuticals Corporation (US) | 2018-05-30 | — | — | EP | claimed |
| US-20180050018-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-02-22 | — | — | US | claimed |
| US-20180042922-A1 | COMPOSITIONS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE | AXOVANT SCIENCES GMBH (CH) | 2018-02-15 | — | — | US | claimed |
| EP-3265466-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | Chase Pharmaceuticals Corporation (US) | 2018-01-10 | — | — | EP | claimed |
| US-6822119-B1 | REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-23 | — | — | US | claimed |
| US-6310103-B1 | ADMINISTERING TO A MAMMAL SUFFERING FROM URINARY INCONTINENCE INCONTINENCE WHILE REDUCING ADVERSE EFFECT ASSOCITED WITH RACEMIC OR R-ENANTIIOMER OF TOLTERODINE, A S(-)-2-(ALPHA-(2-(DIISOPROPYLAMINO)ETHYL)BENZYL)-P-CRESOL | BRIDGE PHARMA, INC. | 2001-10-30 | — | — | US | claimed |
| EP-0924983-A4 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | ABERG GUNNAR (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0924983-A1 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | Aberg, Gunnar (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1998003067-A1 | S(-)-TOLTERODINE IN THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | ABERG GUNNAR (US) | 1998-01-29 | — | — | WO | claimed |
| JP-2664503-B2 | — | — | 1997-10-15 | — | — | JP | claimed |
| EP-0325571-B1 | NEW AMINES, THEIR USE AND PREPARATION | Kabi Pharmacia AB (SE) | 1991-08-07 | — | — | EP | claimed |
| EP-0354234-A1 | NEW AMINES, THEIR USE AND PREPARATION | KabiVitrum AB (SE) | 1990-02-14 | — | — | EP | claimed |
| WO-1989006644-A1 | NEW AMINES, THEIR USE AND PREPARATION | KABIVITRUM AB (SE) | 1989-07-27 | — | — | WO | claimed |
| EP-0325571-A1 | New amines, their use and preparation | Kabi Pharmacia AB (SE) | 1989-07-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050018-A1 | PERIPHERAL-ANTICHOLINERGIC MUSCARINIC AGONIST COMBINATION | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 7/4885 |
| US-20190314354-A1 | MUSCARINIC COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHRM3, CHRM2, CHRM4 | CHRM3 1/4885CHRM2 2/4885CHRM1 5/4885 |
| US-20180360845-A1 | MUSCARINIC COMBINATION OF A SELECTIVE M2-ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR TREATING HYPOCHOLINERGIC DISORDERS | CHRM2, CHRM1, CHRM4 | CHRM3 5/4885CHRM2 1/4885CHRM1 2/4885 |
| US-20180042922-A1 | COMPOSITIONS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE | NEFM, SNCA, CLN6 | CHRM3 588/4885CHRM2 447/4885CHRM1 1256/4885 |
| US-20190091214-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | ACHE, BCHE, CHAT | CHRM3 18/4885CHRM2 11/4885CHRM1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.